OBJECTIVES The goal of this study was to evaluate the impact of hypertension on the outcome of atrial fibrillation (AF) ablation.
A trial fibrillation (AF) and hypertension are 2 distinct, but often related, cardiovascular diseases with a high and increasing incidence in the overall population (1, 2) . Arterial hypertension is a well-known independent risk factor for AF (3) , a risk that is increased especially when hypertension is uncontrolled (4) . The risk of AF in hypertensive compared with normotensive subjects was increased by 1.9 times in the Framingham Heart Study (5) and 1.4 
times in the Manitoba
Follow-Up Study (6) .
The role of different antihypertensive drugs in reducing the risk of incident atrial fibrillation has been investigated in several studies (7, 8) , and only when therapy is targeted at regression or prevention of electrocardiographic left ventricular (LV) hypertrophy may the incidence of new-onset AF be reduced (9) .
In the context of AF catheter ablation through pulmonary vein antrum isolation (PVAI) (10) , hypertension represents one of the main pre-procedural risk factors for AF recurrence (11) , but the impact of uncontrolled hypertension on AF ablation outcome
has not yet been established.
The main scope of this study is to investigate first whether uncontrolled hypertension plays a role in AF recurrence and, second, which is the best ablation strategy in these patients.
METHODS
STUDY POPULATION. A total of 531 consecutive patients undergoing their first AF catheter ablation were enrolled in this prospective study. Patients were classified into 3 groups: patients with uncontrolled hypertension despite medical treatment (group I, n ¼ 160), patients with controlled hypertension through medical therapy (group II, n ¼ 192), and patients without hypertension (group III, n ¼ 179).
Standard definitions of paroxysmal, persistent, and long-standing persistent AF were used (12) . All patients signed an informed written consent for the procedure.
ABLATION PROCEDURE. Anti-arrhythmic drugs (AADs), with the exception of amiodarone, were discontinued 3 to 5 days before the procedure. Patients on amiodarone were asked to discontinue the drug 4 to 6 months before the ablation. Procedures were performed under general anesthesia using most commonly propofol (2 mg/kg), fentanyl (1 to 2 mg/kg), and rocuronium (0.5 to 1.0 mg/kg).
PVAI AND POSTERIOR WALL ABLATION. All patients underwent PVAI and posterior wall isolation.
PVAI has been described in detail elsewhere (15, 16) . were not considered as recurrences.
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Uncontrolled Hypertension and AF Ablation Outcome J U N E 2 0 With multiplicity-adjusted error rate, group I, compared with group III, had a larger LA diameter and higher prevalence of CAD, non-PV triggers, and moderate-to-severe LA scar. Similarly, group II had a larger LA diameter and more prevalence of CAD compared with group III, whereas group II's prevalence of non-PV triggers and moderate-to-severe scar was not different from group III. Group I and group II did not differ in terms of LA diameter and CAD prevalence, whereas group I had more prevalence of non-PV triggers and moderate-to-severe scar. The baseline characteristics with pairwise group comparisons are presented in Table 1 .
The mean duration of hypertension was 9 AE 6 years for the uncontrolled (group I) and 9 AE 7 years for the control group (group II). The mean systolic and diastolic BP in the uncontrolled group were 156.6 AE 7.4 mm Hg and 94.9 AE 4.4 mm Hg, respectively ( Table 2 ).
The majority of the patients had systolic BP between 150 and 159 mm Hg (60%), whereas almost one-half of the patients had diastolic BP between 90 and 94 mm Hg (53.1%). In the uncontrolled hypertension group, the average number of drugs per patient was 3.1 ( Table 3) .
The mean systolic and diastolic BP in the controlled group were 127.7 AE 8.0 mm Hg and 76.5 AE 7.5 mm Hg, respectively. In the controlled hypertension group, the average number of drugs per patient was 1.85 (Table 3) . 
NON-PV TRIGGERS, AF ABLATION APPROACH, AND
PROCEDURE OUTCOME. After a mean follow-up of 19 AE 7.7 months, 95 (59.4%), 138 (71.9 %), and 133 (74.3%) patients in group I, group II, and group III, respectively, achieved success after the first ablation 
Santoro et al. (Figure 1B) , whereas success was very low (37.3%) in group I patients in whom non-PV triggers
were not ablated (group Ib) compared with group II and III (log-rank p < 0.001) ( Figure 1C) . and groin hematoma occurred in 2, 1, and 1 patients in groups 1, 2, and 3, respectively (p ¼ 0.69) ( Table 5) . In patients with uncontrolled hypertension, in addition to the PVs, non-PV triggers became a necessary target for a successful ablation. Indeed, it Further studies are needed on this topic.
Uncontrolled hypertension has to be considered as a pre-procedural AF recurrence risk factor and, together with the type of AF, could predict the progression of atrial disease. Non-PV triggers, recognized during the procedure, represent a target of ablation, and successful elimination of these triggers confers a higher rate of AF freedom.
STUDY LIMITATIONS. This is not a randomized study; the ablation strategy was decided by the operator, so no conclusion can be drawn about the real benefit of additional non-PV trigger ablation.
All the procedures were performed under general anesthesia, which did not allow recognition of all non-PV triggers; however, because patients in both groups received the same anesthesia protocol, it may warrant uniformity of data.
LA dimension was evaluated only through measurement of the anterior-posterior diameter; no data were collected on LA volume and/or area.
Because patients were referred to our institutions only for EP evaluation, no information is available about hypertension management at long-term follow-up. 
CONCLUSIONS

